Previous 10 | Next 10 |
REDWOOD CITY, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that management will present at the 2019 Cantor Fitzgerald Global Healthcare Conference on Friday, October 4 at 12:00 p.m. Eastern time (9:00 a.m. Pacific ...
When investing in stocks , investors should seek great businesses with a history of execution, or at least solid growth potential. A stock priced at $1,000 per share could be a bargain compared to one priced at $10 per share. Nonetheless, less mature businesses -- and those with greater growth ...
InsiderInsights' Daily Round Up articles rate the "Significance" of the Top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the "Significance" of an insider transaction, however, and often not even the most im...
Codexis, Inc. (CDXS) Q2 2019 Results Earnings Conference Call August 6, 2019 04:30 PM ET Company Participants Bruce Voss - LHA John Nicols - President and CEO Gordon Sangster - SVP and Chief Financial Officer Conference Call Participants Brandon Couillard - Jefferies M...
Codexis (NASDAQ: CDXS ): Q2 Non-GAAP EPS of -$0.08 misses by $0.01 ; GAAP EPS of -$0.12 beats by $0.01 . Revenue of $12.3M (-8.9% Y/Y) misses by $1.76M . Press Release More news on: Codexis, Inc., Earnings news and commentary, Healthcare stocks news,
REDWOOD CITY, Calif., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces the appointment of Ross Taylor as Senior Vice President and Chief Financial Officer effective August 19, 2019. Mr. Taylor will be responsible for managing a...
REDWOOD CITY, Calif., July 30, 2019 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that it will report second quarter 2019 financial results after market close on Tuesday, August 6, 2019. Codexis management will hold an investment communit...
REDWOOD CITY, Calif., June 20, 2019 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading synthetic biology company, announces that Casdin Capital, LLC, a New York City-based life science-focused investment firm and current stockholder of Codexis, has invested approximately $50 millio...
REDWOOD CITY, Calif., May 30, 2019 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that management will present at the Jefferies 2019 Global Healthcare Conference on Thursday, June 6 at 2:30 p.m. Eastern time (11:30 a.m. Pacific time). The ...
The following slide deck was published by Codexis, Inc. in conjunction with this Read more ...
News, Short Squeeze, Breakout and More Instantly...
REDWOOD CITY, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the second quarter of 2024 on Thursday, August 8, 2024, following the close of market. Codexis management will ...
REDWOOD CITY, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an asset purchase agreement with Crosswalk Therapeutics for the Company’s investigational Fabry and Pompe disease compounds. Under...
2024-05-30 07:30:04 ET Cantor Fitzgerald analyst issues OVERWEIGHT recommendation for CDXS on May 30, 2024 06:15AM ET. CDXS was trading at $3.19 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy rec...